jabbrv-ltwa-all.ldf jabbrv-ltwa-en.ldf Objective: To analyze adverse event signals of growth hormone based on the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database and provide a reference for safe clinical drug use. Methods: The FAERS database was retrospectively queried to extract reports related to recombinant human growth hormone(rhGH) from 2014 to 2024. Various disproportionality analyses, such as the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS), were used to identify and assess potential adverse events in patients receiving recombinant human growth hormone. Results: We detected 327 valid signals involving 22 SOCs. These included ADEs commonly associated with rhGH such as headache, dizziness, and arthralgia. Unexpected serious ADEs were also identified, including seizures, thrombosis, and gout. The median time to onset of ADEs associated with rhGH was 37.5 days (IQR 0–395 days), with the majority of cases occurring within the first month after administration (n = 3148). However, some ADEs may still occur after 1 year of rhGH treatment (n = 1740). Conclusion: Our investigation revealed several possible safety issues associated with rhGH in real-world clinical practice, which may provide necessary evidence for clinicians and pharmacist managers to be vigilant about the safety of rhGH.